Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

Figure 2

Day 1 Pre-Chemotherapy Platelet Counts for Cycle 1 and Cycle 2 for Individual Patients Who Received Eltrombopag and Completed at Least 2 Cycles (n = 11). Patients indicated with an asterisk (*) received eltrombopag for 10 days post-chemotherapy beginning in Cycle 2; all other patients received eltrombopag beginning in Cycle 2 for 5 days pre- and 5 days post-chemotherapy.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us